AROAF Financials: Aroa Biosurgery Ltd AI Analysis

Home

Stock

AROAF

Financials

AROAF Financial

Aroa Biosurgery Ltd

$0.52

At close: Mar 31, 16:00:00 GMT-4

$0.52

Post-market: Mar 31, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

AROAF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	03/31/2025	03/31/2024	03/31/2023	03/31/2022	03/31/2021
Revenue	90	84	69	63	39	22
Revenue Growth (YoY)	18%	22%	10%	62%	77%	-12%
Cost of Revenue	13	12	10	9	9	6
Gross Profit	76	72	58	53	30	15
Selling, General & Admin	68	66	62	47	30	21
Research & Development	8	9	9	10	7	5
Operating Expenses	76	75	69	56	37	25
Other Non Operating Income (Expenses)	0	0	0	0	0	-1
Pretax Income	-1	-3	-10	0	-8	-19
Income Tax Expense	0	0	0	0	0	0
Net Income	-1	-3	-10	0	-8	-19
Net Income Growth	-86%	-70%	--	-100%	-57.99%	280%
Shares Outstanding (Diluted)	344.96	344.9	343.82	342.91	342.16	300.4
Shares Change (YoY)	0%	0%	0%	0%	14%	10,621%
EPS (Diluted)	0	-0.01	-0.03	0	-0.02	-0.06
EPS Growth	-76%	-64%	2,475%	-95%	-62%	-97%
Free Cash Flow	3	-6	-14	-11	-16	-6
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	84.44%	85.71%	84.05%	84.12%	76.92%	68.18%
Operating Margin	0%	-2.38%	-14.49%	-4.76%	-17.94%	-40.9%
Profit Margin	-1.11%	-3.57%	-14.49%	0%	-20.51%	-86.36%
Free Cash Flow Margin	3.33%	-7.14%	-20.28%	-17.46%	-41.02%	-27.27%
EBITDA	--	-2	-10	-3	-7	-9
EBITDA Margin	--	-2.38%	-14.49%	-4.76%	-17.94%	-40.9%
D&A For EBITDA	--	0	0	0	0	0
EBIT	0	-2	-10	-3	-7	-9
EBIT Margin	0%	-2.38%	-14.49%	-4.76%	-17.94%	-40.9%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Aroa Biosurgery Ltd's key financial statements?



According to the latest financial statement (Form-10K), Aroa Biosurgery Ltd has a total asset of $108, Net loss of $-3

What are the key financial ratios for AROAF?



Aroa Biosurgery Ltd's Current ratio is 7.2, has a Net margin is -3.57, sales per share of $0.24.

How is Aroa Biosurgery Ltd's revenue broken down by segment or geography?



Aroa Biosurgery Ltd largest revenue segment is Soft Tissue Repair Products, at a revenue of 76,443,631 in the most earnings release.For geography, United States is the primary market for Aroa Biosurgery Ltd, at a revenue of 73,903,915.

Is Aroa Biosurgery Ltd profitable?



no, according to the latest financial statements, Aroa Biosurgery Ltd has a net loss of $-3

Does Aroa Biosurgery Ltd have any liabilities?



yes, Aroa Biosurgery Ltd has liability of 15

How many outstanding shares for Aroa Biosurgery Ltd?



Aroa Biosurgery Ltd has a total outstanding shares of 344.9

Key Stats

Prev.Close

$0.522

Open

$0.5

Day's Range

$0.5 - $0.522

52 week range

$0.2439 - $0.522

Volume

35.0K

Avg.Volume

Dividend yield

EPS (TTM)

0.00

Market Cap

$181.0M

What is AROAF?

Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.



Features

AI Copilot for Stock & Crypto

Resources